AI ScreeningAI ChatPricing
  1. JP-listed companies
  2. SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.
  3. Financials
  4. Revenue growth (%)

SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.【JP:2395】

Market cap
¥64.4B
P/E ratio
18.1x
Provides drug development testing services to pharmaceutical companies and operates innovative intranasal drug delivery technology through spinout companies.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndRevenue growth (%) YoY (%)
Mar 31, 202522.6+316.05%
Mar 31, 20245.4-86.90%
Mar 31, 202341.4+136.94%
Mar 31, 202217.5+363.13%
Mar 31, 20213.8-153.78%
Mar 31, 2020-7+23.63%
Mar 31, 2019-5.7+52.01%
Mar 31, 2018-3.7-122.06%
Mar 31, 201716.9-197.75%
Mar 31, 2016-17.3-422.16%
Mar 31, 20155.4-503.76%
Mar 31, 2014-1.3-110.80%
Mar 31, 201312.3

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)